The Maharashtra government has come under scrutiny following revelations that pharmaceutical companies operating in the state have been making exorbitant profits on essential medicines, with a recent survey flagging margins as high as 2,800 percent. Tukaram Mundhe, Maharashtra's Minister for Pharmacy, Drugs and Medical Devices, responded by demanding immediate transparency from drug manufacturers and distributors across the state.
The alarming figures emerged from a survey conducted by the state's drug control department, which examined pricing practices among pharmaceutical firms supplying medicines to government hospitals and public health programmes. According to officials familiar with the findings, some brands of commonly prescribed drugs were being sold at prices that translated into profit margins far exceeding reasonable industry standards.
Speaking to NDTV, Mundhe made it clear that while no industry can be expected to operate at a loss, such extraordinary margins are simply unacceptable. "A trade margin of 2,800 percent is not acceptable, either as a consumer or as a hospital or as a regulator," he stated. The minister emphasized that the government would take concrete steps to ensure pricing transparency and protect patients from exploitative drug pricing.
Pharmaceutical pricing in India has long been a contentious issue. While the National Pharmaceutical Pricing Authority regulates prices for essential drugs under the Drug Price Control Order, many medicines fall outside this framework and are subject to market forces. Critics have frequently argued that excessive markups by distributors and retailers between the manufacturer's price and the point of sale contribute significantly to the final cost borne by consumers and healthcare institutions alike.
Mundhe's intervention signals a likely intensification of regulatory oversight in Maharashtra. Health advocates have welcomed the move, noting that high drug costs remain one of the primary barriers preventing economically vulnerable populations from accessing necessary treatments. The state government is expected to announce further measures in the coming weeks to address what officials describe as systemic opacity in the drug supply chain.
